G

Gabrail Cancer & Research Center | Canton, OH

Research site
(Unclaimed)
Location
4875 Higbee Ave NW, Canton, Ohio, United States of America

Site insights

Top conditions

Top treatments

SGR-1505
Decoy20
Cyclophosphamide
Lenalidomide
ADU-1805
EOS100850
Inupadenant
Interferon
Retifanlimab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 6 total trials

DECOY20 Study in Patients With Advanced Solid Tumors

INDP-D101 is a Phase 1, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of De...

Enrolling
Solid Tumor, Adult
Drug: Decoy20

This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SI...

Enrolling
Solid Tumor, Adult
Refractory Cancer
Drug: ADU-1805
Drug: Pembrolizumab

Primary Objective• Assess the safety and tolerability of low-dose lenalidomide administered by continuous subcutaneous (SC) infusion (STAR-LLD) in co...

Enrolling
Multiple Myeloma
Drug: Lenalidomide

Part 1 of the study determines the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed...

Enrolling
Stage III NSCLC
Metastatic NSCLC
Drug: Pemetrexed
Drug: inupadenant

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD)...

Enrolling
DLBCL Germinal Center B-Cell Type
Waldenstrom Macroglobulinemia
Drug: SGR-1505

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[...

Enrolling
Breast Cancer
Breast Neoplasm
Drug: Cyclophosphamide
Drug: Interferon infiltration of the inoculation site

Trial sponsors

B
I
S
S
S
I

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems